GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ourofino SA (BSP:OFSA3) » Definitions » EV-to-EBIT

Ourofino (BSP:OFSA3) EV-to-EBIT : 7.89 (As of May. 30, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Ourofino EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Ourofino's Enterprise Value is R$1,515 Mil. Ourofino's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was R$192 Mil. Therefore, Ourofino's EV-to-EBIT for today is 7.89.

The historical rank and industry rank for Ourofino's EV-to-EBIT or its related term are showing as below:

BSP:OFSA3' s EV-to-EBIT Range Over the Past 10 Years
Min: -501.26   Med: 16.14   Max: 247.66
Current: 7.88

During the past 11 years, the highest EV-to-EBIT of Ourofino was 247.66. The lowest was -501.26. And the median was 16.14.

BSP:OFSA3's EV-to-EBIT is ranked better than
82.27% of 688 companies
in the Drug Manufacturers industry
Industry Median: 16.935 vs BSP:OFSA3: 7.88

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Ourofino's Enterprise Value for the quarter that ended in Mar. 2025 was R$1,413 Mil. Ourofino's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was R$192 Mil. Ourofino's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 13.60%.


Ourofino EV-to-EBIT Historical Data

The historical data trend for Ourofino's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ourofino EV-to-EBIT Chart

Ourofino Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.43 10.83 8.43 16.68 5.66

Ourofino Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.91 8.35 7.33 5.66 7.35

Competitive Comparison of Ourofino's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Ourofino's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ourofino's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ourofino's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ourofino's EV-to-EBIT falls into.


;
;

Ourofino EV-to-EBIT Calculation

Ourofino's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1515.346/192.161
=7.89

Ourofino's current Enterprise Value is R$1,515 Mil.
Ourofino's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was R$192 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ourofino  (BSP:OFSA3) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Ourofino's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 ) =EBIT / Enterprise Value (Q: Mar. 2025 )
=192.161/1413.1964
=13.60 %

Ourofino's Enterprise Value for the quarter that ended in Mar. 2025 was R$1,413 Mil.
Ourofino's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was R$192 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ourofino EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Ourofino's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Ourofino Business Description

Traded in Other Exchanges
N/A
Address
Anhanguera Highway SP 330, Block C, 2nd floor, Km 298, Industrial District, Cravinhos, SP, BRA, 14140-000
Ourofino SA is engaged in research, development, production and sales of medicines, vaccines and other veterinary products. The company's reportable segments are Production animals, Companion animals, and International operations. It generates maximum revenue from the Production animals segment. The product portfolio includes Anticoccidials, Antimastitics, Biological, Ectoparasiticides, Endectocides, and others.

Ourofino Headlines

No Headlines